News Center

US Supreme Court rejects American Airlines appeal of ruling barring JetBlue alliance

US Supreme Court rejects American Airlines appeal of ruling barring JetBlue alliance

By Nate Raymond (Reuters) -The U.S. Supreme Court rejected on Monday a request by American Airlines (NASDAQ:AAL) to overturn a judicial decision that found that the company’s now-scrapped U.S. Northeast partnership with JetBlue Airways (NASDAQ:JBLU) violated federal antitrust law. The justices turned away an appeal by American Airlines of a lower court’s decision in a lawsuit brought by the U. ...

2025-07-01 00:59:25
Renewable energy stocks react to Senate’s tax bill advancement

Renewable energy stocks react to Senate’s tax bill advancement

Investing.com -- Shares of U.S. renewable energy companies showed mixed results in early Monday trading after the U.S. Senate advanced President Donald Trump’s comprehensive tax-and-spending bill. The legislation preserved tax credits for solar leasing arrangements, where third parties own and install solar panel systems on customers’ properties for a fee. This provision boosted several solar ...

2025-07-01 00:56:53
Europe’s AI gigafactory push attracts 76 bids, EU tech chief says

Europe’s AI gigafactory push attracts 76 bids, EU tech chief says

By Foo Yun Chee BRUSSELS (Reuters) -Seventy-six companies have bid to develop Europe’s artificial intelligence gigafactories, the EU’s tech chief said on Monday, hailing a bigger than expected response to the bloc’s push to catch up with the U.S. and China in this key technology. The European Commission made the announcement four months after it allocated 20 billion euros ($23 billion) in EU ...

2025-07-01 00:53:34
AbbVie to buy Capstan for up to $2.1 billion in immunology push

AbbVie to buy Capstan for up to $2.1 billion in immunology push

By Christy Santhosh (Reuters) -AbbVie said on Monday it would acquire privately held cell therapy developer Capstan Therapeutics in a deal worth up to $2.1 billion, expanding its product pipeline with experimental treatments for autoimmune diseases. The U.S. drugmaker has spent over $20 billion on acquisitions since 2023 as its flagship rheumatoid arthritis drug, Humira, lost patent protection. Ca ...

2025-07-01 00:50:19